for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agile Therapeutics Inc

AGRX.OQ

Latest Trade

2.20USD

Change

0.06(+2.57%)

Volume

776,733

Today's Range

2.19

 - 

2.35

52 Week Range

0.35

 - 

2.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.14
Open
2.35
Volume
776,733
3M AVG Volume
91.27
Today's High
2.35
Today's Low
2.19
52 Week High
2.97
52 Week Low
0.35
Shares Out (MIL)
59.30
Market Cap (MIL)
126.91
Forward P/E
-6.17
Dividend (Yield %)
--

Latest Developments

More

Agile Therapeutics Reports Third-Quarter 2019 Financial Results

Agile Therapeutics Announces Pricing Of $12 Million Underwritten Public Offering Of Common Stock

Agile Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agile Therapeutics Inc

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Industry

Biotechnology & Drugs

Contact Info

101 Poor Farm Rd

+1.609.6831880

https://www.agiletherapeutics.com/

Executive Leadership

Alfred Altomari

Chairman of the Board, President, Chief Executive Officer

Dennis P. Reilly

Chief Financial Officer

Scott M. Coiante

Senior Vice President

Renee Selman

Chief Commercial Officer

Abhijeet J. Lele

Lead Independent Director

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.130

2017

-0.910

2018

-0.580

2019(E)

-0.353
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-59.49
Return on Equity (TTM)
-50.12

Latest News

Latest News

Agile Therapeutics sinks after FDA feedback on contraceptive

Agile Therapeutics Inc's shares sank 75 percent on Friday after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators' issues over its chief experimental product, a contraceptive patch.

Agile Therapeutics exploring funding options after FDA meeting

Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.

BRIEF-Agile Therapeutics Provides Regulatory Update On Twirla® (Ag200-15) For The Prevention Of Pregnancy

* AGILE THERAPEUTICS, INC. PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

BRIEF-Agile Therapeutics Reports Q1 Loss Per Share $0.20

* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Agile Therapeutics Reports Q4 Loss Per Share $0.18

* AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Perceptive Advisors Reports 9.9 Pct Passive Stake In Agile Therapeutics

* Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc As Of Dec 22, 2017 - SEC Filing Source text: (http://bit.ly/2FlgqN8) Further company coverage:

FDA rejects Agile's contraceptive patch, shares plunge

Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.

FDA declines to approve Agile's contraceptive patch

Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods.

BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla

* AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

BRIEF-Agile Therapeutics Q3 loss per share $0.22

* Agile therapeutics reports third quarter 2017 financial results

BRIEF-‍Caxton Corp reports 5.3 pct passive stake in Agile Therapeutics Inc

* Caxton Corp reports 5.3 percent passive stake in Agile Therapeutics Inc as on August 9, 2017 - SEC filing Source text (http://bit.ly/2vKGGOo) Further company coverage:

BRIEF-Agile Therapeutics announces proposed offering of common stock

* Agile Therapeutics announces proposed offering of common stock

BRIEF-Agile Therapeutics reports second quarter 2017 financial results

* Q2 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S

BRIEF-Agile Therapeutics announces FDA acceptance of NDA resubmission of Twirla

* Agile Therapeutics announces FDA acceptance of the NDA resubmission of Twirla®

BRIEF-Agile therapeutics resubmits new drug application for transdermal contraceptive patch

* Agile therapeutics resubmits new drug application (NDA) for its transdermal contraceptive patch, Twirla®

BRIEF-Agile Therapeutics reports Q1 loss per share $0.26

* Agile Therapeutics reports first quarter 2017 financial results

BRIEF-Agile Therapeutics to resubmit Twirla NDA to FDA by Q2 2017-end

* Plans to resubmit its New Drug Application for Twirla to U.S. Food and Drug Administration by end of Q2 of 2017 Source text for Eikon: Further company coverage:

BRIEF-Agile Therapeutics announces results of its pre-submission meeting with FDA

* Agile Therapeutics announces results of its pre-submission meeting with FDA

BRIEF-Agile Therapeutics says it plans to resubmit its NDA for Twirla in 1H 2017

* Agile Therapeutics announces a poster presentation of its secure phase 3 study at the contraceptive technology 2017 conference

BRIEF-Agile Therapeutics Q4 loss per share $0.18

* Agile Therapeutics reports fourth quarter and full year 2016 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up